UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40538 ALPHA TEKNOVA, INC. (Exact name of registrant as specified in its charter) Delaware 94-3368109 (State or other jurisdiction ...

Alpha Teknova (TKNO) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the Tecnova First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw y ...

FINANCIAL RESULTS: Q1:2025 SLIDE SUPPLEMENT Nasdaq: TKNO May 8, 2025 • Welcome • Business Highlights and Updates Stephen Gunstream, President and Chief Executive Officer • Financial Results and 2025 Outlook Matt Lowell, Chief Financial Officer • Q&A Forward-looking statements and use of non-GAAP financial measures Today's Agenda © 2025 Alpha Teknova, Inc. ● Financial Results | Q1:2025 ● Slide Supplement May 8, 2025 2 Statements in this presentation about future expectations, plans, and prospects, as well as ...

Exhibit 99.1 Teknova Reports First Quarter 2025 Financial Results First quarter 2025 total revenue was $9.8 million, up 5% from prior year Company introduced proprietary PluriFreezeTM cryopreservation system, in collaboration with Pluristyx, Inc. Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 8, 2025 – Alpha Teknova, Inc. ("Teknova" or the "Company") (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therap ...

First quarter 2025 total revenue was $9.8 million, up 5% from prior yearCompany introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc.Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today an ...

Core Viewpoint - Alpha Teknova, Inc. is set to report its financial results for Q1 2025 on May 8, 2025, after market close, indicating a focus on transparency and communication with investors [1]. Group 1: Financial Reporting - The company will announce its financial results for the first quarter ended March 31, 2025, on May 8, 2025 [1]. - A webcast and conference call will be held on the same day at 5 p.m. Eastern Time for investors to access the results [2]. Group 2: Company Overview - Teknova has been innovating in the manufacture of critical reagents since 1996, supporting the life sciences industry [3]. - The company offers customizable solutions for various stages of the workflow, aiding in molecular diagnostics, synthetic biology, and emerging therapeutic modalities [3]. - Teknova operates from a 180,000 square feet facility in Hollister, California, designed for efficient production of foundational ingredients for next-generation therapies [3].

Innovative product line is purpose-built to streamline the manufacture of allogeneic cell therapies. Available exclusively from Teknova starting today. HOLLISTER, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (Nasdaq: TKNO), and Pluristyx, Inc., today announced that Pluristyx's PluriFreeze™ cryopreservation system is available for purchase exclusively from Teknova. Teknova is a leading producer of critical reagents for the discovery, development, and commercialization of novel t ...

HOLLISTER, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), and Pluristyx, Inc., today announced that Pluristyx's PluriFreeze™ cryopreservation system is available for purchase exclusively from Teknova. Teknova is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, while Pluristyx is a leading provider of induced Pluripotent Stem Cells (iPSCs), including immune evading ...

Core Insights - Teknova and Pluristyx have announced a collaboration to produce and commercialize the PluriFreeze™ cryopreservation system, aimed at enhancing the development of allogeneic cell therapies [1][2] - Teknova will serve as the exclusive manufacturer and distributor of the PluriFreeze product line in the United States and Canada, facilitating wider access for customers [2][3] Company Overview - Teknova specializes in manufacturing critical reagents for the life sciences industry, supporting the discovery and development of novel therapies, vaccines, and diagnostics [5] - Pluristyx focuses on providing induced Pluripotent Stem Cells (iPSCs) and innovative technologies to accelerate the development lifecycle of cell therapies [6][7] Product Details - The PluriFreeze system includes a protective wash and a low viscosity freezing medium, designed to streamline the manufacturing process of cell products [3][4] - PluriFreeze Base mimics intracellular space and provides metabolic support, while PluriFreeze PF10 contains 10% dimethyl sulfoxide (DMSO) to simplify scale-up and automation [3] Future Developments - Additional information regarding pricing and availability of the PluriFreeze products will be disclosed at the BioProcess International West conference in San Diego, starting March 19, 2025 [4]

Tax Attributes and Financial Liabilities - As of December 31, 2024, the company had $75.3 million of U.S. federal and $69.2 million of state net operating loss carryforwards (NOLs) available to reduce future taxable income[160]. - The deductibility of federal NOLs incurred after December 31, 2021, is limited to 80% of taxable income, affecting future tax planning[160]. - The company’s ability to utilize NOLs may be limited based on its operating performance and tax laws in effect at the time of proposed use[160]. - The company may experience ownership changes that could limit its ability to use pre-change NOLs and other tax attributes, potentially resulting in increased future tax liability[161]. - The company is subject to various tax liabilities, and changes in tax laws could adversely affect its financial condition and results of operations[230]. Intellectual Property and Competitive Position - The company relies on trade secret protection and confidentiality agreements to safeguard its intellectual property, which is critical for its competitive position[165]. - The company does not currently own any issued patents covering its proprietary products or manufacturing processes, which may hinder its ability to protect its innovations[166]. - The company may need to obtain licenses from third parties to advance its research or commercialize products, with no assurance of obtaining such licenses on favorable terms[185]. - The company may face challenges in protecting its trademarks and trade names, which could adversely affect its ability to compete effectively[182]. - Intellectual property litigation could result in significant expenses and distract personnel from their normal responsibilities, potentially impacting the company's financial condition[178]. - The company may face claims from third parties asserting misappropriation of intellectual property, which could lead to costly litigation[180]. - The company’s commercial success depends on obtaining and maintaining trade secret protection for its current and future products[165]. Financial Covenants and Debt Obligations - The company was out of compliance with the revenue covenant under its Amended and Restated Credit Agreement for the periods ending November 30, 2023, and January 31, 2024[196]. - On March 8, 2024, the company entered into Amendment No. 5 to the Amended and Restated Credit Agreement, which included a waiver from the lender for the covenant violations[196]. - The Second Amended and Restated Credit Agreement contains covenants that impose significant operating and financial restrictions on the company[194]. - The company may incur additional indebtedness in the future, which could exacerbate risks associated with its current substantial indebtedness[193]. - The company may be required to divert funds to service its debt, impairing its liquidity position and operational flexibility[190]. - The company expects to use cash on hand to meet current and future financial obligations, including funding operations and debt service requirements[192]. Corporate Governance and Stockholder Rights - THP controls approximately 70.6% of the voting power of the company's outstanding common stock, allowing it to influence corporate decisions significantly[197]. - The company has provisions in its corporate governance documents that could make it more difficult for third parties to acquire it, potentially affecting stockholder interests[212]. - The company has opted out of Section 203 of the Delaware General Corporation Law, which generally restricts business combinations with interested stockholders for three years[214]. - The company’s amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation, which may limit stockholders' options[216]. - The company’s governance provisions may discourage lawsuits against its directors and officers, potentially impacting accountability[218]. Financial Reporting and Compliance - The existence of material weaknesses in internal controls could lead to errors in financial statements, adversely affecting investor confidence and stock price[203]. - The company is required to disclose any material weaknesses in internal control over financial reporting, which could lead to restatements of financial statements[203]. - The company is classified as an "emerging growth company" and a "smaller reporting company," which allows it to take advantage of reduced disclosure requirements, potentially making its common stock less attractive to investors[204]. - The company has elected to utilize the extended transition period for complying with new or revised accounting standards, which may complicate financial comparisons with other public companies[206]. - The company will remain an "emerging growth company" until it exceeds $1.235 billion in annual revenue or meets other specified criteria[207]. - The company is subject to the reporting requirements of the Securities Exchange Act of 1934 and the Sarbanes-Oxley Act, which may strain resources and distract management from growth strategies[210]. Market Conditions and Stock Performance - The company’s operating results and stock price may be volatile, influenced by various factors beyond its control[237]. - If securities or industry analysts do not publish favorable reports or cease coverage, the company's stock price and trading volume could decline[239]. - Analysts' projections may vary significantly from actual business results due to various uncontrollable factors[240]. - If operating results fail to meet expectations, the company's stock price could decline[241]. - The market price of the company's stock could decline if holders of currently restricted shares sell them or are perceived as intending to sell[222]. - The company may face challenges in raising additional funds through future offerings due to market conditions and the perception of its stock[220]. - The company may issue shares of preferred stock in the future, which could adversely affect holders of common stock and depress its market price[225]. - The company does not anticipate paying regular cash dividends on its common stock, as it is prohibited under the Second Amended and Restated Credit Agreement[224]. Shareholder Structure and Equity Plans - As of December 31, 2024, the company has 53,409,727 shares of common stock outstanding, with a significant portion held by directors and affiliates, subject to Rule 144 limitations[221]. - The company has 312,174, 1,527,105, and 2,280,667 shares reserved for issuance under the 2016 Stock Plan, 2020 Equity Incentive Plan, and 2021 Equity Incentive Plan, respectively[223].